

Table S1. Characteristics of patients with acute lymphoblastic leukemia (ALL) according to gender. Data are presented as mean \pm standard deviation (SD).

	Total <i>n</i> =58	Females <i>n</i> =27	Males <i>n</i> =31	<i>p</i> -value (females vs. males)
TAG (mg/dl)	97.65 \pm 48.18	95.77 \pm 51.94	100.50 \pm 43.17	0.543
Apo-A1 (mg/dl)	259.55 \pm 125.56	284.74 \pm 131.92	231.56 \pm 114.02	0.111
Apo-A2 (mg/dl)	24.75 \pm 6.39	25.09 \pm 6.20	24.34 \pm 6.70	0.877
Apo-B (mg/dl)	61.15 \pm 14.86	60.43 \pm 14.71	61.99 \pm 15.29	0.700
Apo-C1 (mg/dl)	20.50 \pm 6.62	20.37 \pm 7.22	20.65 \pm 6.00	0.878
Apo-C3 (mg/dl)	5.33 \pm 1.95	5.47 \pm 1.97	5.18 \pm 1.94	0.596
Apo-D (mg/dl)	3.61 \pm 0.67	3.71 \pm 0.58	3.51 \pm 0.75	0.411
Apo-E (mg/dl)	2.71 \pm 1.09	2.69 \pm 1.05	2.73 \pm 1.15	0.890
Apo-H (mg/dl)	41.56 \pm 10.44	43.02 \pm 9.35	39.93 \pm 11.49	0.544
Apo-J (mg/dl)	11.10 \pm 3.50	11.36 \pm 2.82	10.82 \pm 4.17	0.482
CRP (mg/dl)	0.85 \pm 0.85	0.82 \pm 0.70	0.89 \pm 1.00	0.785

Table S2. Characteristics of patients with acute lymphoblastic leukemia (ALL) according to radiotherapy. Data are presented as mean \pm standard deviation (SD).

	Radiotherapy <i>n</i> =9	Non-radiotherapy <i>n</i> =49	<i>p</i> -value
TAG (mg/dl)	131.00 \pm 58.08	90.03 \pm 43.03	0.059
Apo-A1 (mg/dl)	261.03 \pm 140.56	251.88 \pm 114.88	0.834
Apo-A2 (mg/dl)	24.84 \pm 6.96	24.27 \pm 6.08	0.988
Apo-B (mg/dl)	63.42 \pm 20.89	60.16 \pm 13.70	0.555
Apo-C1 (mg/dl)	21.27 \pm 5.26	19.86 \pm 6.58	0.547
Apo-C3 (mg/dl)	6.06 \pm 2.28	5.03 \pm 1.71	0.127
Apo-D (mg/dl)	3.76 \pm 0.57	3.53 \pm 0.63	0.409
Apo-E (mg/dl)	3.30 \pm 1.76	2.56 \pm 0.88	0.232
Apo-H (mg/dl)	43.88 \pm 6.48	40.36 \pm 10.42	0.283
Apo-J (mg/dl)	12.52 \pm 3.96	10.61 \pm 3.11	0.114
CRP (mg/dl)	1.26 \pm 1.62	0.78 \pm 0.61	0.381

Table S3. Spearman rank correlation of apolipoprotein in patients with acute lymphoblastic leukemia (ALL) depending on selected basic parameters.

Variable		Spearman r	p-value	95% confidence interval
BMI (kg/m ²)	Apo-A1	0.22	0.282	-0.19 – 0.57
	Apo-A2	0.30	0.145	-0.12 – 0.63
	Apo-B	0.31	0.117	-0.09 – 0.63
	Apo-C1	0.26	0.203	-0.15 – 0.59
	Apo-C3	0.60	0.001	0.27 – 0.81
	Apo-D	0.56	0.003	0.21 – 0.78
	Apo-E	0.37	0.063	-0.03 – 0.67
	Apo-H	0.49	0.010	0.12 – 0.74
	Apo-J	0.41	0.037	0.01 – 0.69
	CRP	0.47	0.016	0.09 – 0.73
WHR	Apo-A1	-0.12	0.570	-0.50 – 0.30
	Apo-A2	0.11	0.602	-0.32 – 0.50
	Apo-B	0.25	0.219	-0.17 – 0.60
	Apo-C1	0.16	0.437	-0.26 – 0.53
	Apo-C3	0.04	0.852	-0.37 – 0.44
	Apo-D	0.16	0.434	-0.26 – 0.53
	Apo-E	0.06	0.779	-0.35 – 0.45
	Apo-H	0.07	0.753	-0.35 – 0.46
	Apo-J	0.01	0.950	-0.39 – 0.42
	CRP	0.38	0.059	-0.03 – 0.68
Age at diagnosis (years)	Apo-A1	-0.32	0.104	-0.64 – 0.08
	Apo-A2	-0.16	0.443	-0.53 – 0.26
	Apo-B	0.07	0.717	-0.33 – 0.46
	Apo-C1	0.08	0.699	-0.33 – 0.46
	Apo-C3	0.16	0.444	-0.26 – 0.52
	Apo-D	0.23	0.256	-0.18 – 0.57
	Apo-E	-0.07	0.744	-0.45 – 0.34
	Apo-H	0.17	0.415	-0.25 – 0.53

	Apo-J	-0.07	0.736	-0.45 – 0.34
	CRP	0.32	0.104	-0.08 – 0.64
SBP (mmHg)	Apo-A1	-0.06	0.757	-0.45 – 0.34
	Apo-A2	0.08	0.708	-0.34 – 0.47
	Apo-B	0.22	0.276	-0.19 – 0.57
	Apo-C1	0.32	0.114	-0.09 – 0.63
	Apo-C3	0.46	0.018	0.08 – 0.72
	Apo-D	0.35	0.077	-0.05 – 0.66
	Apo-E	0.32	0.107	-0.08 – 0.64
	Apo-H	0.36	0.071	-0.04 – 0.66
	Apo-J	0.22	0.277	-0.19 – 0.57
	CRP	0.32	0.110	-0.09 – 0.64
DBP (mmHg)	Apo-A1	-0.13	0.536	-0.50 – 0.28
	Apo-A2	0.23	0.263	-0.19 – 0.58
	Apo-B	0.35	0.077	-0.05 – 0.66
	Apo-C1	0.46	0.018	0.08 – 0.72
	Apo-C3	0.35	0.077	-0.05 – 0.66
	Apo-D	0.34	0.087	-0.06 – 0.65
	Apo-E	0.19	0.343	-0.22 – 0.54
	Apo-H	0.36	0.074	-0.05 – 0.66
	Apo-J	0.08	0.683	-0.32 – 0.47
	CRP	-0.04	0.838	-0.43 – 0.36